Mefloquine gap junction blockade and risk of pregnancy loss

Biology of Reproduction

Volumn 87, Issue 3, 2012, Pages

  Nevin, Remington Lee ^a  

^a Bayne Jones Army Community Hospital   (United States)

Author keywords

Decidua; Placenta; Placental transport; Toxicology; Trophoblast

Indexed keywords

GAP JUNCTION PROTEIN ALPHA 1; MEFLOQUINE; MEMBRANE PROTEIN; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ABORTION; BLOOD PLACENTA BARRIER; CELL COMMUNICATION; CONCEPTION; DECIDUA; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; GAP JUNCTION; HUMAN; LIPOPHILICITY; MALARIA; NIDATION; NONHUMAN; PLACENTA; PLACENTA DEVELOPMENT; POSTMARKETING SURVEILLANCE; PREGNANCY; PREGNANCY LOSS; PREGNANT WOMAN; PRIORITY JOURNAL; RISK; SHORT SURVEY; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TROPHOBLAST;

ABORTION, SPONTANEOUS; ANIMALS; ANTIMALARIALS; FEMALE; GAP JUNCTIONS; HUMANS; MALARIA, FALCIPARUM; MEFLOQUINE; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; RISK FACTORS;

EID: 84869398359     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.112.099614     Document Type: Short Survey

References (127)

1. Rieckmann KH, Trenholme GM, Williams RL, Carson PE, Frischer H, Desjardins RE. Prophylactic activity of mefloquine hydrochloride (WR 142490) in drug-resistant malaria. Bull World Health Organ 1974; 51: 375-377.
2. Jones R, Kunsman G, Levine B, Smith M, Stahl C. Mefloquine distribution in postmortem cases. Forensic Sci Int 1994; 68:29-32.
3. Nevin RL. Mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning. Neurotoxicology 2011; 32:986-987.
4. Nevin RL. Mefloquine prescriptions in the presence of contraindications: prevalence among U.S. military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 2010; 19:206-210.
5. Milatovic D, Aschner M. Response to Nevin, RL: mefloquine neurotoxicity and gap junction blockade: critical insights in drug repositioning. Neurotoxicology 2011; 32:987.
6. MacArthur JR, Parise ME, Steketee RW. Relationships between mefloquine blood levels, gender, and adverse reactions. Am J Trop Med Hyg 2002; 66:445.
7. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33:226-234.
8. Bradley DJ, Warhurst DC. Malaria prophylaxis: guidelines for travellers from Britain. Malaria Reference Laboratory of the Public Health Laboratory Service, London. BMJ 1995; 310:709-714.
9. Baily G, Fraser IS, Dunbar EM, Wilkins EG. Malaria prophylaxis. Mefloquine should be first choice. BMJ 1993; 307:1564.
10. EVans MR. Adverse events associated with mefloquine. Patients may start to take cheaper over the counter regimens. BMJ 1996; 313:1554.
11. Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, Parise M, Odero M, Waiyaki P. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med 2001; 8:167-172.
12. Ingram RJ, Ellis-Pegler RB. Malaria, mefloquine and the mind. N Z Med J 1997; 110:137-138.
13. Van Riemsdijk MM, Sturkenboom MC, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BH. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002; 72:294-301.
14. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicenter, randomized, double blind, four arm study. BMJ 2003; 327:1078.
15. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313:525-528.
16. Van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002; 58:441-445.
17. Willmore CB, Ayesu LW. Keeping score on psychiatric drug effects: is mefloquine safe for malaria chemoprophylaxis? J Pharm Technol 2006; 22:32-41.
18. Van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 2004; 57: 506-512.
19. Schlagenhauf P, Johnson R, Schwartz E, Nothdurft HD, Steffen R. Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study. J Travel Med 2009; 16:42-45.
20. Van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry 2005; 66:199-204.
21. Hill D.R. Pretravel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. Am J Trop Med Hyg 1991; 45:263-270.
22. Nevin RL, Pietrusiak PP, Caci JB. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J 2008; 7:30.
23. Leggat PA, Speare R. Trends in antimalarial drugs prescribed in Australia 1992 to 1998. J Travel Med 2003; 10:189-191.
24. Leggat PA. Trends in antimalarial prescriptions in Australia from 1998 to 2002. J Travel Med 2005; 12:338-342.
25. Leggat PA. Trends in antimalarial prescriptions in Australia 2002 to 2005. J Travel Med 2008; 15:302-306.
26. Clift S, Grabowski P. Malaria prophylaxis and the media. Lancet 1996; 348:344.
27. Zuckerman JN, Batty AJ, Jones ME. Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: retrospective observational data. Travel Med Infect Dis 2009; 7:329-336.
28. Larocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, Hagmann S, Vinetz J, Connor BA, Goad JA, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers-analysis of demographic characteristics, travel destinations, and pretravel health care of high-risk U.S. international travelers, 2009-2011. Clin Infect Dis 2012; 54:455-462.
29. Strauch S, Jantratid E, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. J Pharm Sci 2011; 100:11-21.
30. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008; 359:603-612.
31. Schlagenhauf P, Adamcova M, Regep L, Schaerer M.T, Rhein H.G. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010; 9:357.
32. Irvine MH, Einarson A, Bozzo P. Prophylactic use of antimalarials during pregnancy. Can Fam Physician 2011; 57:1279-1281.
33. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998; 5:121-126.
34. Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL. The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of U.S. Army servicewomen. J Infect Dis 1997; 176:831-833.
35. Nosten F, ter Kuile F, Maelankiri L, Chongsuphajaisiddhi T, Nopdonrattakoon L, Tangkitchot S, Boudreau E, Bunnag D, White NJ. Mefloquine prophylaxis prevents malaria during pregnancy: a doubleblind, placebo-controlled study. J Infect Dis 1994; 169:595-603.
36. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, De Vries A, Chongsuphajaisiddhi T, White NJ. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999; 28:808-815.
37. Lariam [package insert]. Nutley, NJ: F. Hoffmann-La Roche Ltd; 1989.
38. Update: New Recommendations for Mefloquine Use in Pregnancy [Internet]. Atlanta, GA: Centers For Disease Control and Prevention. http://www.cdc.gov/malaria/new_info/2011/mefloquine_pregnancy.html. Accessed 15 June 2012.
39. Advising Travelers with Special Needs-Pregnant Travelers [Internet]. Atlanta, GA: Centers for Disease Control and Prevention. http://wwwnc. cdc.gov/travel/yellowbook/2012/chapter-8-advising-travelers-withspecific-needs/pregnant-travelers.htm. Accessed 15 June 2012.
40. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 1996; 55(suppl 1):33-41.
41. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55(suppl 1):50-56.
42. Rowland M, Nosten F. Malaria epidemiology and control in refugee camps and complex emergencies. Ann Trop Med Parasitol 2001; 95: 741-754.
43. Briand V, Cottrell G, Massougbodji A, Cot M. Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas. Malar J 2007; 6:160.
44. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005; 2:e3.
45. Briand V, Bottero J, Noël H, Masse V, Cordel H, Guerra J, Kossou H, Fayomi B, Ayemonna P, Fievet N, Massougbodji A, Cot M. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 2009; 200:991-1001.
46. Chico RM, Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Trop Med Int Health 2011; 16(7):774-785.
47. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003; 8: 488-506.
48. A Strategic Framework for Malaria Prevention and Control during Pregnancy in the African Region [Internet]. Brazzaville, Congo: World Health Organization. http://whqlibdoc.who.int/afro/2004/AFR_MAL_04. 01.pdf. Accessed 15 June 2012.
49. Assessment of the Safety of Artemisinin Compounds in Pregnancy: Report of Two Joint Informal Consultations Convened in 2006 (WHO/ Cds/Mal/2003.1094) [Internet]. Geneva, Switzerland: World Health Organization. http://whqlibdoc.who.int/publications/2007/9789241596114_eng.pdf. Accessed 15 June 2012.
50. Malaria. In: International Travel and Health 2012. Geneva: World Health Organization; 2012:142-164. http://www.who.int/ith/ITH2010chapter7. pdf.
51. Cruikshank SJ, Hopperstad M, Younger M, Connors BW, Spray DC, Srinivas M. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A 2004; 101:12364-12369.
52. Kara F, Cinar O, Erdemli-Atabenli E, Tavil-Sabuncuoglu B, Can A. Ultrastructural alterations in human decidua in miscarriages compared to normal pregnancy decidua. Acta Obstet Gynecol Scand 2007; 86: 1079-1086.
53. Yu J, Wu J, Bagchi IC, Bagchi MK, Sidell N, Taylor RN. Disruption of gap junctions reduces biomarkers of decidualization and angiogenesis and increases inflammatory mediators in human endometrial stromal cell cultures. Mol Cell Endocrinol 2011; 344:25-34.
54. Nevin RL. Mefloquine blockade of connexin 43 (Cx43) and risk of pregnancy loss. Placenta 2011; 32:712.
55. Schwartz DE, Weber W, Richard-Lenoble D, Gentilini M. Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man. Acta Trop 1980; 37:238-242.
56. Ramathal CY, Bagchi IC, Taylor RN, Bagchi MK. Endometrial decidualization: of mice and men. Semin Reprod Med 2010; 28:17-26.
57. Grümmer R, Winterhager E. Regulation of gap junction connexins in the endometrium during early pregnancy. Cell Tissue Res 1998; 293: 189-194.
58. Nair RR, Jain M, Singh K. Reduced expression of gap junction gene connexin 43 in recurrent early pregnancy loss patients. Placenta 2011; 32:619-621.
59. Dunk CE, Gellhaus A, Drewlo S, Baczyk D, Pötgens AJ, Winterhager E, Kingdom JC, Lye SJ. The molecular role of connexin 43 in human trophoblast cell fusion. Biol Reprod 2012; 86:115.
60. Grümmer R, Reuss B, Winterhager E. Expression pattern of different gap junction connexins is related to embryo implantation. Int J Dev Biol 1996; 40:361-367.
61. Grümmer R, Traub O, Winterhager E. Gap junction connexin genes cx26 and cx43 are differentially regulated by ovarian steroid hormones in rat endometrium. Endocrinology 1999; 140:2509-2516.
62. Laws MJ, Taylor RN, Sidell N, DeMayo FJ, Lydon JP, Gutstein DE, Bagchi MK, Bagchi IC. Gap junction communication between uterine stromal cells plays a critical role in pregnancy-associated neovascularization and embryo survival. Development 2008; 135:2659-2668.
63. Kibschull M, Gellhaus A, Winterhager E. Analogous and unique functions of connexins in mouse and human placental development. Placenta 2008; 29:848-854.
64. Cronier L, Defamie N, Dupays L, Théveniau-Ruissy M, Goffin F, Pointis G, Malassiné A. Connexin expression and gap junctional intercellular communication in human first trimester trophoblast. Mol Hum Reprod 2002; 8:1005-1013.
65. Malassiné A, Cronier L. Involvement of gap junctions in placental functions and development. Biochim Biophys Acta 2005; 1719:117-124.
66. Bloor DJ, Wilson Y, Kibschull M, Traub O, Leese HJ, Winterhager E, Kimber SJ. Expression of connexins in human preimplantation embryos in vitro. Reprod Biol Endocrinol 2004; 2:25.
67. Gabriel LA, Sachdeva R, Marcotty A, Rockwood EJ, Traboulsi EI. Oculodentodigital dysplasia: new ocular findings and a novel connexin 43 mutation. Arch Ophthalmol 2011; 129:781-784.
68. Juszczak GR, Swiergiel AH. Properties of gap junction blockers and their behavioral, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:181-198.
69. Lariam [package insert]. Nutley, NJ: F. Hoffmann-La Roche Ltd; 2009.
70. Jaspers CA, Hopperus Buma AP, Van Thiel PP, Van Hulst RA, Kager PA. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55:230-234.
71. Schwartz E, Paul F, Pener H, Almog S, Rotenberg M, Golenser J. Malaria antibodies and mefloquine levels among United Nations troops in Angola. J Travel Med 2001; 8:113-116.
72. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 2001; 65:189-192.
73. Charles BG, Blomgren A, Nasveld PE, Kitchener SJ, Jensen A, Gregory RM, Robertson B, Harris IE, Reid MP, Edstein MD. Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. Eur J Clin Pharmacol 2007; 63:271-278.
74. Weidekamm E, Rüsing G, Caplain H, Sörgel F, Crevoisier C. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 1998; 54:615-619.
75. Doberstyn EB, Phintuyothin P, Noeypatimanondh S, Teerakiartkamjorn C. Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine. Bull World Health Organ 1979; 57:275-279.
76. de Souza JM, Heizmann P, Schwartz DE. Single-dose kinetics of mefloquine in Brazilian male subjects. Bull World Health Organ 1987;65:353-356.
77. Pennie RA, Koren G, Crevoisier C. Steady state pharmacokinetics of mefloquine in long-term travellers. Trans R Soc Trop Med Hyg 1993; 87:459-462.
78. Mu JY, Israili ZH, Dayton PG. Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090. Drug Metab Dispos 1975; 3:198-210.
79. Chevli R, Fitch CD. The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother 1982; 21:581-586.
80. San George RC , Nagel RL, Fabry ME. On the mechanism for the redcell accumulation of mefloquine, an antimalarial drug. Biochim Biophys Acta 1984; 803:174-181.
81. Milner E, Sousa J, Pybus B, Melendez V, Gardner S, Grauer K, Moon J,Carroll D, Auschwitz J, Gettayacamin M, Lee P, Leed S, et al.Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. Eur J Drug Metab Pharmacokinet 2011; 36:151-158.
82. Franssen G, Rouveix B, Lebras J, Bauchet J, Verdier F, Michon C,Bricaire F. Divided-dose kinetics of mefloquine in man. Br J Clin Pharmacol 1989; 28:179-184.
83. Simpson JA, Aarons L, Price R, White NJ. The influence of body weight on the pharmacokinetics of mefloquine. Br J Clin Pharmacol 2002; 53: 337-338.
84. Kollaritsch H, Karbwang J, Wiedermann G, Mikolasek A, Na-Bangchang K, Wernsdorfer WH. Mefloquine concentration profiles during prophylactic dose regimens. Wien Klin Wochenschr 2000; 112:441-447.
85. Wiedermann G, Kollaritsch H, Kundi M, Wernsdorfer WH. Relationships between mefloquine blood levels, gender, and adverse reactions.Am J Trop Med Hyg 2002; 66:445-446.
86. Potasman I, Juven Y, Weller B, Schwartz E. Does mefloquine prophylaxis affect electroencephalographic patterns? Am J Med 2002;112:147-149.
87. Na Bangchang K, Davis TM, Looareesuwan S, White NJ, Bunnag D,Karbwang J. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg 1994; 88:321-323.
88. Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: asystematic review. Clin Pharmacokinet 2011; 50:705-723.
89. Barzago MM, Omarini D, Bortolotti A, Stellari FF, Lucchini G, Efrati S,Bonati M. Mefloquine transfer during in vitro human placenta perfusion.J Pharmacol Exp Ther 1994; 269:28-31.
90. Azpurua H, Funai EF, Coraluzzi LM, Doherty LF, Sasson IE, Kliman M,Kliman HJ. Determination of placental weight using two-dimensional sonography and volumetric mathematic modeling. Am J Perinatol 2010;27:151-155.
91. Van Der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW,Russel FG. Mechanisms of drug transfer across the human placenta.Pharm World Sci 1998; 20:139-148.
92. Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol 2011; 12:674-685.
93. Young AM, Allen CE, Audus KL. Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003; 55:125-132.
94. Barraud De Lagerie S, Comets E, Gautrand C, Fernandez C, Auchere D,Singlas E, Mentre F, Gimenez F. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 2004; 141:1214-1222.
95. Finstad CL, Saigo PE, Rubin SC, Federici MG, Provencher DM, Hoskins WJ, Lewis JL Jr, Lloyd KO. Immunohistochemical localization of Pglycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J Histochem Cytochem 1990; 38:1677-1681.
96. Axiotis CA, Monteagudo C, Merino MJ, LaPorte N, Neumann RD.Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol 1991; 138:799-806.
97. Kuo DY, Mallick S, Shen HJ, DeVictoria C, Jones J, Fields AL,Goldberg GL, Runowicz CD, Horwitz SB. Analysis of MDR1 expression in normal and malignant endometrium by reverse transcriptionpolymerase chain reaction and immunohistochemistry. Clin Cancer Res 1996; 2:1981-1992.
98. Axiotis CA, Guarch R, Merino MJ, Laporte N, Neumann RD. Pglycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 1991; 65:577-581.
99. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta:expression, localization, regulation and function. Reprod Toxicol 2006;22:400-410.
100. Evseenko DA, Paxton JW, Keelan JA. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 2007; 35:595-601.
101. Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule.Am J Obstet Gynecol 2008. 198:126e1-4.
102. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005; 26:268-270.
103. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W.Expression of the multidrug resistance P-glycoprotein, (ABCB1glycoprotein) in the human placenta decreases with adVancing gestation.Placenta 2006; 27:602-609.
104. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994; 26:417-423.
105. Atkinson DE, Sibley CP, Fairbairn LJ, Greenwood SL. MDR1 P-gpexpression and activity in intact human placental tissue; upregulation by retroviral transduction. Placenta 2006; 27:707-714.
106. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL,Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010; 79:921-925.
107. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M,Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of Pglycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
108. Rahi M, Heikkinen T, Härtter S, Hakkola J, Hakala K, Wallerman O,Wadelius M, Wadelius C, Laine K. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 2007; 21:751-756.
109. Beghin D, Delongeas JL, Claude N, Farinotti R, Forestier F, Gil S.Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicol In Vitro 2010; 24:630-637.
110. Camus M, Deloménie C, Didier N, Faye A, Gil S, Dauge MC, Mabondzo A, Farinotti R. Increased expression of MDR1 mRNAs and Pglycoprotein in placentas from HIV-1 infected women. Placenta 2006;27:699-706.
111. Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP,Canfield RE, Armstrong EG, Nisula BC. Incidence of early loss of pregnancy. N Engl J Med 1988; 319:189-194.
112. Vanhauwere B, Maradit H, Kerr L. Postmarketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy. Am J Trop Med Hyg 1998; 58:17-21.
113. Review of Adverse Events Associated with Lariam (mefloquine):Introduction to Jan 1, 1994 Basel, Switzerland: F. Hoffman-La Roche Ltd.; 1994.
114. Review of Adverse Events Associated with Lariam (Mefloquine):January 1, 1994, to December 31, 1994. Basel, Switzerland: F. Hoffman-La Roche Ltd.; 1995.
115. Lariam (Mefloquine) Report: January 1, 1995, to December 31, 1995.Research Report No. B-166584. Basel, Switzerland; F. Hoffman-La Roche Ltd.;1996.
116. Gullahorn GM, Bohman HR, Wallace MR. Anaesthesia emergence delirium after mefloquine prophylaxis. Lancet 1993; 341:632.
117. Wallace MR, Sharp TW, Smoak B, Iriye C, Rozmajzl P, Thornton SA,Batchelor R, Magill AJ, Lobel HO, Longer CF, Burans JP. Malaria among United States troops in Somalia. Am J Med 1996; 100:49-55.
118. Sánchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in U.S. troops in Somalia. Lancet 1993; 341:1021-1022.
119. Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G,Schaerer MT, Boutros MS, Rhein HG, Adamcova M. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54:e124-e131.
120. Nevin RL. Limitations of postmarketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure.Clin Infect Dis 2012; (in press). Published online ahead of print 3 July 2012; DOI 10.1093/cid/cis601.
121. Krikun G, Mor G, Alvero A, Guller S, Schatz F, Sapi E, Rahman M,Caze R, Qumsiyeh M, Lockwood CJ. A novel immortalized human endometrial stromal cell line with normal progestational response.Endocrinology 2004; 145:2291-2296.
122. Hellgren U, Rombo L. Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view. J Travel Med 2010; 17:130-132.
123. Dannenberg AL, Dorfman SF, Johnson J. Use of quinine for self-induced abortion. South Med J 1983; 76:846-849.
124. Smith JP. Risky choices: the dangers of teens using self-induced abortion attempts. J Pediatr Health Care 1998; 12:147-151.
125. Drance SM. Quinine amaurosis. Br J Ophthalmol 1955; 39:178-181.
126. Flick L, Mumford J. Quinine amblyopia; treatment by stellate ganglion block. Br Med J 1955; 2:94-96.
127. Lewis BS. A case of acute quinine poisoning. J R Nav Med Serv 1950;36:38-40.